3 279

Cited 76 times in

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production

Authors
 Tae Woo Jung  ;  Ji Young Lee  ;  Bong Soo Cha  ;  Hyun Chul Lee  ;  Chul Woo Ahn  ;  Soo Kyung Kim  ;  Eun Seok Kang  ;  Wan Sub Shim 
Citation
 JOURNAL OF THE NEUROLOGICAL SCIENCES, Vol.253(1-2) : 53-60, 2007 
Journal Title
 JOURNAL OF THE NEUROLOGICAL SCIENCES 
ISSN
 0022-510X 
Issue Date
2007
MeSH
1-Methyl-4-phenylpyridinium/toxicity* ; Caspase 3/metabolism ; Cell Line, Tumor ; Cytochromes c/metabolism ; Herbicides/toxicity* ; Humans ; Hypoglycemic Agents/pharmacology* ; Mitochondria/drug effects ; Mitochondria/metabolism ; Neuroblastoma ; Neurons/cytology ; Neurons/drug effects* ; Neurons/metabolism ; Neuroprotective Agents/pharmacology ; Oxidative Stress/drug effects* ; Proto-Oncogene Proteins c-bcl-2/genetics ; RNA, Messenger/metabolism ; Reactive Oxygen Species/metabolism ; Rosiglitazone ; Thiazolidinediones/pharmacology* ; bcl-2-Associated X Protein/genetics
Keywords
MPP+ ; Rosiglitazone ; ROS ; Bcl-2 ; Bax ; Parkison's disease
Abstract
1-Methyl-4-phenylpyridinium ion (MPP+), an inhibitor of mitochondrial complex I, has been widely used as a neurotoxin because it elicits a severe Parkinson's disease-like syndrome with elevation of intracellular reactive oxygen species (ROS) level and apoptotic death. Rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been known to show various non-hypoglycemic effects, including anti-inflammatory, anti-atherogenic, and anti-apoptotic. In the present study, we investigated the protective effects of rosiglitazone on MPP+ induced cytotoxicity in human neuroblastoma SH-SY5Y cells, as well as underlying mechanism. Our results suggested that the protective effects of rosiglitazone on MPP+ induced apoptosis may be ascribed to its anti-oxidative properties, anti-apoptotic activity via inducing expression of SOD and catalase and regulating the expression of Bcl-2 and Bax. These data indicated that rosiglitazone might provide a valuable therapeutic strategy for the treatment of progressive neurodegenerative disease such as Parkinson's disease.
Full Text
http://www.sciencedirect.com/science/article/pii/S0022510X06005399
DOI
10.1016/j.jns.2006.11.020
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Medical Research Center (임상의학연구센터) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Soo Kyung(김수경)
Shim, Wan Sub(심완섭)
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Hyun Chul(이현철)
Jung, Tae Woo(정태우)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/96691
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse